NTRK gene fusion testing and management in lung cancer.
Loading...
Embargo End Date
ICR Authors
Authors
Repetto, M
Chiara Garassino, M
Loong, HH
Lopez-Rios, F
Mok, T
Peters, S
Planchard, D
Popat, S
Rudzinski, ER
Drilon, A
Zhou, C
Chiara Garassino, M
Loong, HH
Lopez-Rios, F
Mok, T
Peters, S
Planchard, D
Popat, S
Rudzinski, ER
Drilon, A
Zhou, C
Document Type
Journal Article
Date
2024-06-01
Date Accepted
2024-04-02
Abstract
Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are recurrent oncogenic drivers found in a variety of solid tumours, including lung cancer. Several tropomyosin receptor kinase (TRK) inhibitors have been developed to treat tumours with NTRK gene fusions. Larotrectinib and entrectinib are first-generation TRK inhibitors that have demonstrated efficacy in patients with TRK fusion lung cancers. Genomic testing is recommended for all patients with metastatic non-small cell lung cancer for optimal drug therapy selection. Multiple testing methods can be employed to identify NTRK gene fusions in the clinic and each has its own advantages and limitations. Among these assays, RNA-based next-generation sequencing (NGS) can be considered a gold standard for detecting NTRK gene fusions; however, several alternatives with minimally acceptable sensitivity and specificity are also available in areas where widespread access to NGS is unfeasible. This review highlights the importance of testing for NTRK gene fusions in lung cancer, ideally using the gold-standard method of RNA-based NGS, the various assays that are available, and treatment algorithms for patients.
Citation
Cancer Treatment Reviews, 2024, 127 pp. 102733 -
Source Title
Cancer Treatment Reviews
Publisher
ELSEVIER SCI LTD
ISSN
0305-7372
eISSN
1532-1967
1532-1967
1532-1967